Extract from the Register of European Patents

EP Citations: EP2350279

Cited inInternational search
Type:Patent literature
Publication No.:WO2006023544  [I]
 (QUARK BIOTECH INC et al.) [I] 1-11,15,17,19,23-58,62,64,66,70-73 * page 126 - page 127 * * page 142, line 8 *
Type:Patent literature
Publication No.:WO2004103389  [I]
 (THERAPTOSIS SA et al.) [I] 1-11,15,17,19,23-58,62,64,66,70-73 * page 7, line 29 - line 31 * * page 4, line 13 - line 16 * * page 14, line 28 - line 30 *
Type:Patent literature
Publication No.:US2006172965  [X]
 (SHEPARD ALLAN R et al.) [X] 1 * paragraph [0008] * * paragraph [0170] *
Type:Patent literature
Publication No.:WO2004078940  [X]
 (SENESCO TECHNOLOGIES INC et al.) [X] 1 * page 27, line 16 - line 19 *
Type:Patent literature
Publication No.:WO2009044392  [XP]
 (QUARK PHARMACEUTICALS INC et al.) [XP] 43-47,52,56 * page 108 - page 109; example 6A *
Type:Non-patent literature
Publication information:[X]   MUCKE H A M: "New ocular therapeutics: A view from the patenting perspective", IDRUGS, CURRENT DRUGS LTD, GB, vol. 10, no. 1, 1 January 2007 (2007-01-01), pages 37 - 41, XP009095914, ISSN: 1369-7056 [X] 1 * page 40 *
Type:Non-patent literature
Publication information:[A]   SINGH M ET AL: "CELL-SPECIFIC CASPASE EXPRESSION BY DIFFERENT NEURONAL PHENOTYPES IN TRANSIENT RETINAL ESCHEMIA", JOURNAL OF NEUROCHEMISTRY, WILEY INTERSCIENCE, NEW YORK, NY, US, vol. 77, no. 2, 1 January 2001 (2001-01-01), pages 466 - 475, XP008047223, ISSN: 0022-3042 [A] 1-73 * the whole document *
DOI: http://dx.doi.org/10.1046/j.1471-4159.2001.00258.x
Cited inExamination
Type:Patent literature
Publication No.:WO2008050329  
Type:Non-patent literature
Publication information:  Z AHMED ET AL: "Ocular neuroprotection by siRNA targeting caspase-2", CELL DEATH AND DISEASE, vol. 2, no. 6, 1 June 2011 (2011-06-01), pages e173, XP055059532, DOI: 10.1038/cddis.2011.54 [P]
DOI: http://dx.doi.org/10.1038/cddis.2011.54